Completely mismatched allogeneic CD3/CD28 cross-linked Th1 memory cells elicit anti-leukemia effects in unconditioned hosts without GVHD toxicity

Leukemia Research

Volumn 32, Issue 12, 2008, Pages 1903-1913

  Har Noy, M ^a,c   Zeira, M ^a   Weiss, L ^a   Slavin, S ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c Immunovative Therapies Ltd   (Israel)

Author keywords

Allogeneic cell therapy; Graft vs. host disease; Graft vs. leukemia; Immunotherapy; Leukemia treatment

Indexed keywords

ALLOANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; CROSS LINKING; DOSE RESPONSE; DRUG EFFECT; FEMALE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; IMMUNE RESPONSE; LEUKEMIA; MALE; MEMORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL;

ANIMALS; ANTIGENS, CD28; ANTIGENS, CD3; BONE MARROW TRANSPLANTATION; CROSS-LINKING REAGENTS; DISEASE MODELS, ANIMAL; FEMALE; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOLOGIC MEMORY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; SURVIVAL ANALYSIS; TH1 CELLS; TRANSPLANTATION, HOMOLOGOUS;

EID: 51649121034     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.05.007     Document Type: Article

References (63)

1. van Rhee F., Szydlo R.M., Hermans J., Devergie A., Frassoni F., Arcese W., et al. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 20 (1997) 553
2. Sohn S.K., Kim D.H., Kim J.G., Sung W.J., Baek J.H., Lee N.Y., et al. Outcome of allogeneic peripheral blood stem cell transplantation using matched sibling donors in patients with high-risk hematological diseases. Eur J Haematol 72 (2004) 430
3. Slavin S., Nagler A., Shapira M., Panigrahi S., Samuel S., and Or A. Non-myeloablative allogeneic stem cell transplantation focusing on immunotherapy of life-threatening malignant and non-malignant diseases. Crit Rev Oncol Hematol 39 (2001) 25
4. Slavin S., Morecki S., Weiss L., and Or R. Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation. J Hematother Stem Cell Res 11 (2002) 265
5. Giralt S., Khouri I., and Champlin R. Non myeloablative "mini transplants". Cancer Treat Res 101 (1999) 97
6. Childs R., and Barrett J. Nonmyeloablative stem cell transplantation for solid tumors: expanding the application of allogeneic immunotherapy. Semin Hematol 39 (2002) 63
7. Bay J.O., Fleury J., Choufi B., Tournilhac O., Vincent C., Bailly C., et al. Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients. Bone Marrow Transplant 30 (2002) 95
8. Dazzi F., Szydlo R.M., Cross N.C., Craddock C., Kaeda J., Kanfer E., et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 96 (2000) 2712
9. Fowler D.H. Shared biology of GVHD and GVT effects: potential methods of separation. Crit Rev Oncol Hematol 57 (2006) 225
10. Weiden P.L., Flournoy N., Thomas E.D., Prentice R., Fefer A., Buckner C.D., et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 300 (1979) 1068
11. Sullivan K.M., Storb R., Buckner C.D., Fefer A., Fisher L., Weiden P.L., et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 320 (1989) 828
12. Kernan N.A., Collins N.H., Juliano L., Cartagena T., Dupont B., and O'Reilly R.J. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood 68 (1986) 770
13. Ferrara J.L., and Deeg H.J. Graft-versus-host disease. N Engl J Med 324 (1991) 667
14. Champlin R., Giralt S., and Gajewski J. T cells, graft-versus-host disease and graft-versus-leukemia: innovative approaches for blood and marrow transplantation. Acta Haematol 95 (1996) 157
15. Rubio M.T., Kim Y.M., Sachs T., Mapara M., Zhao G., and Sykes M. Antitumor effect of donor marrow graft rejection induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: critical role for recipient-derived IFN-gamma. Blood 102 (2003) 2300
16. Kraus A.B., Shaffer J., Toh H.C., Preffer F., Dombkowski D., Saidman S., et al. Early host CD8 T-cell recovery and sensitized anti-donor interleukin-2-producing and cytotoxic T-cell responses associated with marrow graft rejection following nonmyeloablative allogeneic bone marrow transplantation. Exp Hematol 31 (2003) 609
17. Rubio M.T., Saito T.I., Kattleman K., Zhao G., Buchli J., and Sykes M. Mechanisms of the antitumor responses and host-versus-graft reactions induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: a critical role for recipient CD4+ T cells and recipient leukocyte infusion-derived IFN-gamma-producing CD8+ T cells. J Immunol 175 (2005) 665
18. Saito T.I., Rubio M.T., and Sykes M. Clinical relevance of recipient leukocyte infusion as antitumor therapy following nonmyeloablative allogeneic hematopoietic cell transplantation. Exp Hematol 34 (2006) 1271
19. Rubio M.T., Zhao G., Buchli J., Chittenden M., and Sykes M. Role of indirect allo- and autoreactivity in anti-tumor responses induced by recipient leukocyte infusions (RLI) in mixed chimeras prepared with nonmyeloablative conditioning. Clin Immunol 120 (2006) 33
20. Rosenberg S.A., Yang J.C., and Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat Med 10 (2004) 909
21. Rabinovich G.A., Gabrilovich D., and Sotomayor E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25 (2007) 267
22. Har-Noy M., and Slavin S. The anti-tumor effect of allogeneic bone marrow/stem cell transplant without graft vs. host disease toxicity and without a matched donor requirement?. Med Hypotheses 70 6 (2008) 1186
23. Slavin S., and Strober S. Spontaneous murine B-cell leukemia. Nature 272 (1978) 624
24. Aslakson C.J., and Miller F.R. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52 (1992) 1399
25. Pugatsch T., Oppenheim A., and Slavin S. Improved single-step PCR assay for sex identification post-allogeneic sex-mismatched BMT. Bone Marrow Transplant 17 (1996) 273
26. Bland J.M., and Altman D.G. The logrank test. Bmj 328 (2004) 1073
27. Spruance S.L., Reid J.E., Grace M., and Samore M. Hazard ratio in clinical trials. Antimicrob Agents Chemother 48 (2004) 2787
28. Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev 8 (2003) 223
29. Aruga A., Aruga E., Tanigawa K., Bishop D.K., Sondak V.K., and Chang A.E. Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role. J Immunol 159 (1997) 664
30. Zhou J., Ye F., Chen H., Lv W., and Gan N. The expression of interleukin-10 in patients with primary ovarian epithelial carcinoma and in ovarian carcinoma cell lines. J Int Med Res 35 (2007) 290
31. Ikeda H., Chamoto K., Tsuji T., Suzuki Y., Wakita D., Takeshima T., et al. The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci 95 (2004) 697
32. Levings M.K., and Roncarolo M.G. T-regulatory 1 cells: a novel subset of CD4 T cells with immunoregulatory properties. J Allergy Clin Immunol 106 (2000) S109
33. Marshall N.A., Christie L.E., Munro L.R., Culligan D.J., Johnston P.W., Barker R.N., et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 103 (2004) 1755
34. Simeonovic C.J., Townsend M.J., Karupiah G., Wilson J.D., Zarb J.C., Mann D.A., et al. Analysis of the Th1/Th2 paradigm in transplantation: interferon-gamma deficiency converts Th1-type proislet allograft rejection to a Th2-type xenograft-like response. Cell Transplant 8 (1999) 365
35. Conrad R., Remberger M., Cederlund K., Hentschke P., Sundberg B., Ringden O., et al. Inflammatory cytokines predominate in cases of tumor regression after hematopoietic stem cell transplantation for solid cancer. Biol Blood Marrow Transplant 12 (2006) 346
36. De L.K.T., Whiting C.V., and Bland P.W. Proinflammatory cytokine synthesis by mucosal fibroblasts from mouse colitis is enhanced by interferon-gamma-mediated up-regulation of CD40 signalling. Clin Exp Immunol 147 (2007) 313
37. Kilinc M.O., Aulakh K.S., Nair R.E., Jones S.A., Alard P., Kosiewicz M.M., et al. Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors. J Immunol 177 (2006) 6962
38. Kim E.Y., Lee E.N., Lee J., Park H.J., Chang C.Y., Jung da Y., et al. Two-signal blockade with anti-CD45RB and anti-CD154 monoclonal antibodies inhibits graft rejection via CD4-dependent mechanisms in allogeneic skin transplantation. Exp Mol Med 38 (2006) 284
39. Tomihara K., Kato K., Masuta Y., Nakamura K., Tanaka T., Hiratsuka H., et al. Gene transfer of the CD40-ligand to human dendritic cells induces NK-mediated antitumor effects against human carcinoma cells. Int J Cancer 120 (2007) 1491
40. Hunter T.B., Alsarraj M., Gladue R.P., Bedian V., and Antonia S.J. An agonist antibody specific for CD40 induces dendritic cell maturation and promotes autologous anti-tumour T-cell responses in an in vitro mixed autologous tumour cell/lymph node cell model. Scand J Immunol 65 (2007) 479
41. Snijders A., Kalinski P., Hilkens C.M., and Kapsenberg M.L. High-level IL-12 production by human dendritic cells requires two signals. Int Immunol 10 (1998) 1593
42. Cella M., Scheidegger D., Palmer-Lehmann K., Lane P., Lanzavecchia A., and Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 184 (1996) 747
43. Steinman R.M. Linking innate to adaptive immunity through dendritic cells. Novartis Found Symp 279 (2006) 101
44. Georgopoulos N.T., Steele L.P., Thomson M.J., Selby P.J., Southgate J., and Trejdosiewicz L.K. A novel mechanism of CD40-induced apoptosis of carcinoma cells involving TRAF3 and JNK/AP-1 activation. Cell Death Differ 13 (2006) 1789
45. Georgopoulos N.T., Merrick A., Scott N., Selby P.J., Melcher A., and Trejdosiewicz L.K. CD40-mediated death and cytokine secretion in colorectal cancer: a potential target for inflammatory tumour cell killing. Int J Cancer (2007)
46. Tong A.W., Papayoti M.H., Netto G., Armstrong D.T., Ordonez G., Lawson J.M., et al. Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. Clin Cancer Res 7 (2001) 691
47. von Leoprechting A., van der Bruggen P., Pahl H.L., Aruffo A., and Simon J.C. Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis. Cancer Res 59 (1999) 1287
48. Loskog A., and Totterman T.H. CD40L-a multipotent molecule for tumor therapy. Endocr Metab Immune Disord Drug Targets 7 (2007) 23
49. Koguchi Y., Thauland T.J., Slifka M.K., and Parker D.C. Preformed CD40 ligand exists in secretory lysosomes in effector and memory CD4+ T cells and is quickly expressed on the cell surface in an antigen specific manner. Blood 110 October (7) (2007) 2520 [Epub 2007 Jun 26]
50. Casamayor-Palleja M., Khan M., and MacLennan I.C. A subset of CD4+ memory T cells contains preformed CD40 ligand that is rapidly but transiently expressed on their surface after activation through the T cell receptor complex. J Exp Med 181 (1995) 1293
51. Lee T.H., Donegan E., Slichter S., and Busch M.P. Transient increase in circulating donor leukocytes after allogeneic transfusions in immunocompetent recipients compatible with donor cell proliferation. Blood 85 (1995) 1207
52. Zitvogel L., Casares N., Pequignot M.O., Chaput N., Albert M.L., and Kroemer G. Immune response against dying tumor cells. Adv Immunol 84 (2004) 131
53. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410 (2001) 1107
54. Borg C., Terme M., Taieb J., Menard C., Flament C., Robert C., et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest 114 (2004) 379
55. Whiteside T.L., and Herberman R.B. The role of natural killer cells in immune surveillance of cancer. Curr Opin Immunol 7 (1995) 704
56. Nishimura T., Nakui M., Sato M., Iwakabe K., Kitamura H., Sekimoto M., et al. The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother Pharmacol 46 Suppl. (2000) S52
57. Chamoto K., Kosaka A., Tsuji T., Matsuzaki J., Sato T., Takeshima T., et al. Critical role of the Th1/Tc1 circuit for the generation of tumor-specific CTL during tumor eradication in vivo by Th1-cell therapy. Cancer Sci 94 (2003) 924
58. Winter H., Hu H.M., Poehlein C.H., Huntzicker E., Osterholzer J.J., Bashy J., et al. Tumour-induced polarization of tumour vaccine-draining lymph node T cells to a type 1 cytokine profile predicts inherent strong immunogenicity of the tumour and correlates with therapeutic efficacy in adoptive transfer studies. Immunology 108 (2003) 409
59. Stremmel C., Greenfield E.A., Howard E., Freeman G.J., and Kuchroo V.K. B7-2 expressed on EL4 lymphoma suppresses antitumor immunity by an interleukin 4-dependent mechanism. J Exp Med 189 (1999) 919
60. Lee P.P., Zeng D., McCaulay A.E., Chen Y.F., Geiler C., Umetsu D.T., et al. T helper 2-dominant antilymphoma immune response is associated with fatal outcome. Blood 90 (1997) 1611
61. Hsieh C.S., Macatonia S.E., O'Garra A., and Murphy K.M. T cell genetic background determines default T helper phenotype development in vitro. J Exp Med 181 (1995) 713
62. Hosken N.A., Shibuya K., Heath A.W., Murphy K.M., and O'Garra A. The effect of antigen dose on CD4+ T helper cell phenotype development in a T cell receptor-alpha beta-transgenic model. J Exp Med 182 (1995) 1579
63. Bretscher P.A., Wei G., Menon J.N., and Bielefeldt-Ohmann H. Establishment of stable, cell-mediated immunity that makes "susceptible" mice resistant to Leishmania major. Science 257 (1992) 539